| Identification | Back Directory | [Name]
CC-90010 | [CAS]
1706738-98-8 | [Synonyms]
CC-90010
Trotabresib
Trotabresib (CC-90010)
Trotabresib (Synonyms: CC-90010)
1(2H)-Isoquinolinone, 4-[2-(cyclopropylmethoxy)-5-(methylsulfonyl)phenyl]-2-methyl- | [Molecular Formula]
C21H21NO4S | [MDL Number]
MFCD32874157 | [MOL File]
1706738-98-8.mol | [Molecular Weight]
383.46 |
| Chemical Properties | Back Directory | [Boiling point ]
625.6±55.0 °C(Predicted) | [density ]
1.302±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 50 mg/mL (130.39 mM; Need ultrasonic) | [form ]
A solid | [pka]
-2.80±0.70(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
CC-90010 (compound 1) is a reversible and orally active BET inhibitor. CC-90010 is applied in the study for advanced solid tumors[1][2]. | [References]
[1] CELGENE QUANTICEL RESEARCH, INC. PROCESS FOR THE PREPARATION OF BROMODOMAIN INHIBITOR. Patent. WO2020023438.
[2] V. Moreno, et al. CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study. |
|
|